At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 49 enrolled
Drug / intervention
Febuxostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)
In Brief
A Phase 4 clinical trial evaluating Febuxostat and Placebo for Hypertension. Completed, enrolled 49 participants across 1 site.
Detailed Summary
In this study the investigators will recruit hypertensive subjects with higher than average uric acid levels to test the effect of lowering uric acid with febuxostat on several measures as listed below. This will be a randomized, double-blind, placebo-controlled, parallel group study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedApr 2011
Primary CompletionSep 2013
Study CompletionJan 2014
TodayJul 2026
First PostedApr 5, 2011
Enrollment StartMar 1, 2011
Primary CompletionSep 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.2 years ago
Interventions
Febuxostatdrug
Placebodrug